中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2012年
1期
11-14
,共4页
热休克蛋白110%T淋巴细胞%免疫应答%肿瘤疫苗
熱休剋蛋白110%T淋巴細胞%免疫應答%腫瘤疫苗
열휴극단백110%T림파세포%면역응답%종류역묘
Heat shock protein 110%T lymphocyte%Immunoresponse%Tumor vaccine
目的 探讨重组人热休克蛋白(HSP)1 10-HER2/neu胞内区(ICD)复合物免疫Bal B/c小鼠的脾细胞毒性T淋巴细胞(CTL)反应.方法 利用D2F2细胞构建高表达HER2/neu的小鼠乳腺癌模型,分别以磷酸盐缓冲液(PBS)、HSP110、HSP110-P789-797复合物和HSP110-HER2/neu ICD复合物免疫小鼠.采用酶联免疫斑点法检测T细胞分泌γ-干扰素( IFN-γ)的水平,采用颗粒酶释放法检测CTL反应.结果 免疫组化检测显示,高表达HER2/neu的小鼠乳腺癌模型构建成功.PBS组、HSP110组、HER2/neu ICD组、HSP110-P789-797组和HSP1 10-HER2/neu ICD组蓝色斑点数量分别为(4.57±1.33)个、(6.83±2.08)个、(16.17±2.86)个、(43.67±4.78)个和(76.51±8.17)个.HSP1 10-HER2/neu ICD组与HSP110-P789-797组、HSP110-P789-797组与HER2/neu ICD组相比,分泌IFN-γ的小鼠脾细胞数量明显增多(P＜0.01).PBS组、HSP110组、HER2/neu ICD组、HSP110-P789-797组和HSP110-HER2/neu ICD组小鼠CTL对靶细胞的杀伤率分别为(8.15±1.27)％、(9.51±1.51)％、(14.03±2.45)％、(25.99±3.04)％和(38.15±3.95)％.HSP110-HER2/neu ICD组与HSP110-P789-797组、HSP110-P789-797组与HER2/neu ICD组相比,靶细胞杀伤率亦增高(均P＜0.01).结论 HSP110-HER2/neu ICD复合物可刺激T淋巴细胞增殖为CTL,针对HER2/neu靶点产生抗肿瘤效应.
目的 探討重組人熱休剋蛋白(HSP)1 10-HER2/neu胞內區(ICD)複閤物免疫Bal B/c小鼠的脾細胞毒性T淋巴細胞(CTL)反應.方法 利用D2F2細胞構建高錶達HER2/neu的小鼠乳腺癌模型,分彆以燐痠鹽緩遲液(PBS)、HSP110、HSP110-P789-797複閤物和HSP110-HER2/neu ICD複閤物免疫小鼠.採用酶聯免疫斑點法檢測T細胞分泌γ-榦擾素( IFN-γ)的水平,採用顆粒酶釋放法檢測CTL反應.結果 免疫組化檢測顯示,高錶達HER2/neu的小鼠乳腺癌模型構建成功.PBS組、HSP110組、HER2/neu ICD組、HSP110-P789-797組和HSP1 10-HER2/neu ICD組藍色斑點數量分彆為(4.57±1.33)箇、(6.83±2.08)箇、(16.17±2.86)箇、(43.67±4.78)箇和(76.51±8.17)箇.HSP1 10-HER2/neu ICD組與HSP110-P789-797組、HSP110-P789-797組與HER2/neu ICD組相比,分泌IFN-γ的小鼠脾細胞數量明顯增多(P＜0.01).PBS組、HSP110組、HER2/neu ICD組、HSP110-P789-797組和HSP110-HER2/neu ICD組小鼠CTL對靶細胞的殺傷率分彆為(8.15±1.27)％、(9.51±1.51)％、(14.03±2.45)％、(25.99±3.04)％和(38.15±3.95)％.HSP110-HER2/neu ICD組與HSP110-P789-797組、HSP110-P789-797組與HER2/neu ICD組相比,靶細胞殺傷率亦增高(均P＜0.01).結論 HSP110-HER2/neu ICD複閤物可刺激T淋巴細胞增殖為CTL,針對HER2/neu靶點產生抗腫瘤效應.
목적 탐토중조인열휴극단백(HSP)1 10-HER2/neu포내구(ICD)복합물면역Bal B/c소서적비세포독성T림파세포(CTL)반응.방법 이용D2F2세포구건고표체HER2/neu적소서유선암모형,분별이린산염완충액(PBS)、HSP110、HSP110-P789-797복합물화HSP110-HER2/neu ICD복합물면역소서.채용매련면역반점법검측T세포분비γ-간우소( IFN-γ)적수평,채용과립매석방법검측CTL반응.결과 면역조화검측현시,고표체HER2/neu적소서유선암모형구건성공.PBS조、HSP110조、HER2/neu ICD조、HSP110-P789-797조화HSP1 10-HER2/neu ICD조람색반점수량분별위(4.57±1.33)개、(6.83±2.08)개、(16.17±2.86)개、(43.67±4.78)개화(76.51±8.17)개.HSP1 10-HER2/neu ICD조여HSP110-P789-797조、HSP110-P789-797조여HER2/neu ICD조상비,분비IFN-γ적소서비세포수량명현증다(P＜0.01).PBS조、HSP110조、HER2/neu ICD조、HSP110-P789-797조화HSP110-HER2/neu ICD조소서CTL대파세포적살상솔분별위(8.15±1.27)％、(9.51±1.51)％、(14.03±2.45)％、(25.99±3.04)％화(38.15±3.95)％.HSP110-HER2/neu ICD조여HSP110-P789-797조、HSP110-P789-797조여HER2/neu ICD조상비,파세포살상솔역증고(균P＜0.01).결론 HSP110-HER2/neu ICD복합물가자격T림파세포증식위CTL,침대HER2/neu파점산생항종류효응.
Objective To explore the cytotoxic responses of spleen T lymphocytes (CTL) in BALB/c mice induced by recombinant HSP110-HER2/neu ICD complex.Methods Tumor-bearing mouse model was immunized by HSP110-HER2/neu ICD complex.The IFN-γ level secreted by activated spleen T lymphocytes was detected by enzyme linked immunospot assay (ELISPOT).The corresponding CTL activity was measured by granzyme release assay.Results The BALB/c mouse model of human mammary tumor highly expressing HER2/neu was established. HSP110-HER2/neu ICD complex immunization led to a significantly higher level of INF-γ than that in HSP110-P789-797 immunized and HER2/neu ICD immunized mice.HSP110-HER2/neu ICD complex immunized animals also show significant CTL activity.The results of immunohistochemical staining showed that the number of blue spots in the PBS group was 4.57 ± 1.33,HSP110 group 6.83 ± 2.08,HER2/neu ICD group 16.17 ± 2.86,HSP110-P789-797 group 43.67 ± 4.78,and SP110-HER2/neu ICD group 76.51 ± 8.17.The number of IFN-γ-secreting spleen lymphocytes in the HSP110-HER2/neu ICD group was significantly higher than that in the HSP110-P789-797 group,and that of HSP110-P789-797 group was significantly higher than that of HER2/neu ICD group ( P ＜ 0.01 ).The target cell-killing rate of the PBS group was ( 8.15 ± 1.27) ％,HSP110 group (9.51 ± 1.51 ) ％,HER2/neu ICD group ( 14.03 ± 2.45 ) ％,HSP110-P789-797 group ( 25.99 ± 3.04 ) ％ and HSP110-HER2/neu ICD group (38.15 ± 3.95) ％ ( all P ＜ 0.01 ).Conclusions HSP110-HER2/neu ICD complex can promote the proliferation and maturation of T lymphocytes into CTLs,and might be used as anti-tumor vaccine to induce potent cytotoxic T lymophocyte immunoresponse against specific tumor cells.
